Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Syuji Takei, Naomi Iwata, Ichiro Kobayashi, Toru Igarashi, Yoko Yoshinaga, Naoko Matsubara, Naomi Sunaga, Ayumi Ito & Shumpei Yokota. (2021) Safety and effectiveness of adalimumab in Japanese patients with juvenile idiopathic arthritis: Results from a real-world postmarketing study. Modern Rheumatology 31:2, pages 421-430.
Read now
Read now
Cheryl A Arcinue, Khayyam Durrani, Pichaporn Artornsombudh, Alaa Radwan, Ravi Parikh, Ana M Suelves, Sana S Siddique, Ian Chang, Janine M Preble & Charles Stephen Foster. (2015) The efficacy and safety of adalimumab in ocular inflammatory disease. Orphan Drugs: Research and Reviews 5, pages 69-74.
Read now
Read now
Francesco Semeraro, Barbara Arcidiacono, Giuseppe Nascimbeni, Martina Angi, Barbara Parolini & Ciro Costagliola. (2014) Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis. Drug Design, Development and Therapy 8, pages 341-348.
Read now
Read now
Sumita Phatak, Rupesh Agrawal & Carlos Pavesio. (2014) Adalimumab: viable treatment option for pediatric refractory uveitis?. Expert Review of Ophthalmology 9:3, pages 175-184.
Read now
Read now
Miguel Cordero-Coma, Taygan Yilmaz & Sumru Onal. (2013) Systematic Review of Anti-Tumor Necrosis Factor-alpha Therapy for Treatment of Immune-mediated Uveitis. Ocular Immunology and Inflammation 21:1, pages 19-27.
Read now
Read now
Katherine Anne B Marzan. (2012) Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions. Adolescent Health, Medicine and Therapeutics 3, pages 85-93.
Read now
Read now
Kaisu Kotaniemi, Hanna Säilä & Hannu Kautiainen. (2011) Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clinical Ophthalmology 5, pages 1425-1429.
Read now
Read now
Articles from other publishers (26)
H. Dele Davies. 2023. Principles and Practice of Pediatric Infectious Diseases. Principles and Practice of Pediatric Infectious Diseases
674
678.e3
.
Roberta Ponti, Maria Vincenza Mastrolia & Gabriele Simonini. (2021) Non-infectious Chronic Uveitis in Childhood: Assessment and Treatment in the Biological Era. Current Treatment Options in Rheumatology 7:1, pages 82-97.
Crossref
Crossref
Mohsen Jari, Reza Shiari, Omid Salehpour & Khosro Rahmani. (2020) Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis. Orphanet Journal of Rare Diseases 15:1.
Crossref
Crossref
Hana Malcová. (2020) Recommendations for the Management of Uveitis Associated with Juvenile Idiopathic Arthritis: The Czech and Slovak Adaptation of the Share Initiative. Czech and Slovak Ophthalmology 76:4, pages 182-196.
Crossref
Crossref
Roberta Ponti, Maria Vincenza Mastrolia & Gabriele Simonini. (2020) Non-Infectious Chronic Uveitis in Childhood: Assessment and Treatment in the Biological Era. Current Treatment Options in Rheumatology 6:3, pages 228-244.
Crossref
Crossref
Natalia Cabrera, Jean-Christophe Lega, Behrouz Kassai, Carine Wouters, Anuela Kondi, Elvira Cannizzaro, Andreas Woerner, Aurelie Chausset, Samuel Roethlisberger, Cyril Jeanneret, Florence Aeschlimann, Salma Malik, Agnès Duquesne, Daniela Kaiser, Laetitia Higel, Anne Maes, Gerald Berthet, Veronique Hentgen, Isabelle Kone-Paut, Alexandre Belot & Michael Hofer. (2020) Sécurité des agents biologiques dans les maladies rhumatismales pédiatriques : étude rétrospective multicentrique en situation réelle dans la base de données JIRcohorte. Revue du Rhumatisme 87:1, pages 43-50.
Crossref
Crossref
A. Heiligenhaus, K. Minden, C. Tappeiner, H. Baus, B. Bertram, C. Deuter, I. Foeldvari, D. Föll, M. Frosch, G. Ganser, M. Gaubitz, A. Günther, C. Heinz, G. Horneff, C. Huemer, I. Kopp, C. Lommatzsch, T. Lutz, H. Michels, T. Neß, U. Neudorf, U. Pleyer, M. Schneider, H. Schulze-Koops, S. Thurau, M. Zierhut & H.W. Lehmann. (2019) Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Seminars in Arthritis and Rheumatism 49:1, pages 43-55.
Crossref
Crossref
Natalia Cabrera, Jean-Christophe Lega, Behrouz Kassai, Carine Wouters, Anuela Kondi, Elvira Cannizzaro, Andreas Woerner, Aurelie Chausset, Samuel Roethlisberger, Cyril Jeanneret, Florence Aeschlimann, Salma Malik, Agnès Duquesne, Daniela Kaiser, Laetitia Higel, Anne Maes, Gerald Berthet, Veronique Hentgen, Isabelle Kone-Paut, Alexandre Belot & Michael Hofer. (2019) Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database. Joint Bone Spine 86:3, pages 343-350.
Crossref
Crossref
Matthew L. Stoll, Chung H. Kau, Peter D. Waite & Randy Q. Cron. (2018) Temporomandibular joint arthritis in juvenile idiopathic arthritis, now what?. Pediatric Rheumatology 16:1.
Crossref
Crossref
H. Dele Davies. 2018. Principles and Practice of Pediatric Infectious Diseases. Principles and Practice of Pediatric Infectious Diseases
651
656.e3
.
H. Dele Davies, Carrie L. Byington, Yvonne A. Maldonado, Elizabeth D. Barnett, Kathryn M. Edwards, Ruth Lynfield, Flor M. Munoz-Rivas, Dawn L. Nolt, Ann-Christine Nyquist, Mobeen H. Rathore, Mark H. Sawyer, William J. Steinbach, Tina Q. Tan & Theoklis E. Zaoutis. (2016) Infectious Complications With the Use of Biologic Response Modifiers in Infants and Children. Pediatrics 138:2.
Crossref
Crossref
V. Gerloni, I. Pontikaki & F. Fantini. 2016. Pediatrics in Systemic Autoimmune Diseases. Pediatrics in Systemic Autoimmune Diseases
471
501
.
Christoph Tappeiner, Sandra Schenck, Martina Niewerth, Arnd Heiligenhaus, Kirsten Minden & Jens Klotsche. (2015) Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database. Arthritis Care & Research 68:1, pages 46-54.
Crossref
Crossref
Heinrike Schmeling, Kirsten Minden, Ivan Foeldvari, Gerd Ganser, Tony Hospach & Gerd Horneff. (2014) Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry. Arthritis & Rheumatology 66:9, pages 2580-2589.
Crossref
Crossref
Gabriele Simonini, Druce Katie, Rolando Cimaz, Gary J. Macfarlane & Gareth T. Jones. (2014) Does switching anti-TNFα biologic agents represent an effective option in childhood chronic uveitis: The evidence from a systematic review and meta-analysis approach. Seminars in Arthritis and Rheumatism 44:1, pages 39-46.
Crossref
Crossref
Marieke H Otten, Janneke Anink, Sandra Spronk & Lisette W A van Suijlekom-Smit. (2013) Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Annals of the Rheumatic Diseases 72:11, pages 1806-1812.
Crossref
Crossref
S. S. Toussi, N. Pan, H. M. Walters & T. J. Walsh. (2013) Infections in Children and Adolescents With Juvenile Idiopathic Arthritis and Inflammatory Bowel Disease Treated With Tumor Necrosis Factor- Inhibitors: Systematic Review of the Literature. Clinical Infectious Diseases 57:9, pages 1318-1330.
Crossref
Crossref
Matthew L. Stoll & Randy Q. Cron. (2013) Treatment of Juvenile Idiopathic Arthritis in the Biologic Age. Rheumatic Disease Clinics of North America 39:4, pages 751-766.
Crossref
Crossref
Ajay Tambralli, Timothy Beukelman, Peter Weiser, Thomas Prescott Atkinson, Randy Quentin Cron & Matthew Laurence Stoll. (2013) High Doses of Infliximab in the Management of Juvenile Idiopathic Arthritis. The Journal of Rheumatology 40:10, pages 1749-1755.
Crossref
Crossref
Emmett T. CunninghamJrJr. (2013) Treatment of chronic noninfectious uveitis in children—the trend toward tumor necrosis factor-alpha inhibition. Journal of American Association for Pediatric Ophthalmology and Strabismus 17:5, pages 451-453.
Crossref
Crossref
J. Anink, M. H. Otten, S. L. Gorter, F. H. M. Prince, M. A. J. van Rossum, J. M. van den Berg, P. A. van Pelt, S. Kamphuis, D. M. C. Brinkman, W. A. A. Swen, J. F. Swart, N. M. Wulffraat, K. M. Dolman, Y. Koopman-Keemink, E. P. A. H. Hoppenreijs, W. Armbrust, R. ten Cate & L. W. A. van Suijlekom-Smit. (2013) Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?. Rheumatology 52:9, pages 1674-1679.
Crossref
Crossref
Wendy J. Ungar, Vania Costa, Heather F. Burnett, Brian M. Feldman & Ronald M. Laxer. (2013) The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: A systematic review. Seminars in Arthritis and Rheumatism 42:6, pages 597-618.
Crossref
Crossref
Andreas Woerner & Nicole Ritz. (2013) Infections in Children Treated With Biological Agents. Pediatric Infectious Disease Journal 32:3, pages 284-288.
Crossref
Crossref
MARIA E. ZANNIN, CAROLINA BIROLO, VALERIA M. GERLONI, ELISABETTA MISEROCCHI, IRENE PONTIKAKI, MARIA P. PAROLI, CLAUDIA BRACAGLIA, ALISON SHARDLOW, FULVIO PARENTIN, ROLANDO CIMAZ, GABRIELE SIMONINI, FERNANDA FALCINI, FABRIZIA CORONA, STEFANIA VIOLA, RICCARDO DE MARCO, LUCIANA BREDA, FRANCESCO LA TORRE, FABIO VITTADELLO, GIORGIA MARTINI & FRANCESCO ZULIAN. (2013) Safety and Efficacy of Infliximab and Adalimumab for Refractory Uveitis in Juvenile Idiopathic Arthritis: 1-year Followup Data from the Italian Registry. The Journal of Rheumatology 40:1, pages 74-79.
Crossref
Crossref
Bernardo Frider, Andres Bruno, Marcelo Ponte & Marcelo Amante. (2013) Drug-Induced Liver Injury Caused by Adalimumab: A Case Report and Review of the Bibliography. Case Reports in Hepatology 2013, pages 1-3.
Crossref
Crossref
Katherine Anne B. Marzan & Bracha Shaham. (2012) Early Juvenile Idiopathic Arthritis. Rheumatic Disease Clinics of North America 38:2, pages 355-372.
Crossref
Crossref